ValuEngine downgraded shares of Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) from a hold rating to a sell rating in a report released on Thursday.

A number of other equities research analysts have also recently commented on SBPH. Chardan Capital initiated coverage on shares of Spring Bank Pharmaceuticals in a report on Monday, May 1st. They issued a buy rating and a $16.50 target price for the company. JMP Securities initiated coverage on shares of Spring Bank Pharmaceuticals in a report on Friday, May 19th. They issued a market perform rating and a $20.00 target price for the company. Cantor Fitzgerald initiated coverage on shares of Spring Bank Pharmaceuticals in a report on Wednesday, July 19th. They issued an overweight rating and a $29.00 target price for the company. Finally, Dawson James reaffirmed a buy rating on shares of Spring Bank Pharmaceuticals in a report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $26.33.

Shares of Spring Bank Pharmaceuticals (NASDAQ:SBPH) traded down 1.87% during mid-day trading on Thursday, hitting $12.58. The company had a trading volume of 6,454 shares. Spring Bank Pharmaceuticals has a 1-year low of $6.31 and a 1-year high of $16.97. The company has a 50-day moving average price of $13.86 and a 200-day moving average price of $11.56. The company’s market capitalization is $159.73 million.

ILLEGAL ACTIVITY NOTICE: “Spring Bank Pharmaceuticals, Inc. (SBPH) Downgraded by ValuEngine to Sell” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/25/spring-bank-pharmaceuticals-inc-sbph-downgraded-by-valuengine-to-sell.html.

In other news, Director Kurt M. Eichler purchased 76,923 shares of the business’s stock in a transaction that occurred on Tuesday, June 27th. The stock was purchased at an average cost of $13.00 per share, with a total value of $999,999.00. Following the completion of the acquisition, the director now directly owns 582,533 shares of the company’s stock, valued at approximately $7,572,929. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David Arkowitz purchased 2,500 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were purchased at an average cost of $12.24 per share, with a total value of $30,600.00. Following the completion of the acquisition, the director now directly owns 17,086 shares of the company’s stock, valued at $209,132.64. The disclosure for this purchase can be found here. Insiders have purchased 81,423 shares of company stock valued at $1,055,319 over the last three months. 17.60% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. DAFNA Capital Management LLC purchased a new position in Spring Bank Pharmaceuticals during the second quarter valued at about $217,000. C WorldWide Group Holding A S purchased a new position in Spring Bank Pharmaceuticals during the second quarter valued at about $340,000. EAM Investors LLC purchased a new position in Spring Bank Pharmaceuticals during the second quarter valued at about $578,000. Private Capital Advisors Inc. boosted its position in Spring Bank Pharmaceuticals by 50.0% in the second quarter. Private Capital Advisors Inc. now owns 56,250 shares of the company’s stock valued at $762,000 after buying an additional 18,750 shares in the last quarter. Finally, Vanguard Group Inc. purchased a new position in Spring Bank Pharmaceuticals during the second quarter valued at about $794,000. 10.13% of the stock is owned by hedge funds and other institutional investors.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Receive News & Stock Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.